Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Zymeworks ( (ZYME) ).
On November 16, 2025, Scott Platshon resigned from Zymeworks‘ board but was appointed as Acting Chief Investment Officer on November 18, 2025. The company announced a strategic initiative to optimize cash flows from its licensed products, including Ziihera, and authorized a $125 million share repurchase program, aiming to fund operations beyond 2028 and enhance shareholder value.
The most recent analyst rating on (ZYME) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
Zymeworks’ overall stock score is driven by strong revenue growth and promising clinical data, which are offset by profitability challenges and cash flow issues. The technical indicators suggest positive momentum, but valuation remains a concern due to negative earnings. The earnings call provided a positive sentiment, but highlighted some risks, including program discontinuation and cash burn.
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a biotechnology company focused on managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics.
Average Trading Volume: 903,948
Technical Sentiment Signal: Buy
Current Market Cap: $1.4B
See more insights into ZYME stock on TipRanks’ Stock Analysis page.